41 results on '"Van Laethem, J."'
Search Results
2. Regorafenib after failure of gemcitabine and platinum-based chemotherapy for locally advanced/metastatic biliary tumors: REACHIN, a randomized, double-blind, phase II trial
3. Adjuvant FOLFOX +/− cetuximab in fullRAS andBRAF wildtype stage III colon cancer patients
4. The multidisciplinary management of gastro-oesophageal junction tumours: European Society of Digestive Oncology (ESDO): Expert discussion and report from the 16th ESMO World Congress on Gastrointestinal Cancer, Barcelona
5. A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial
6. How to identify older patients with cancer who should benefit from comprehensive geriatric assessment?
7. New strategies and designs in pancreatic cancer research: consensus guidelines report from a European expert panel
8. Feasibility of radiotherapy with concomitant gemcitabine and oxaliplatin in locally advanced pancreatic cancer and distal cholangiocarcinoma: a prospective dose finding phase I–II study
9. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab
10. Pathological complete response after neoadjuvant immunotherapy for a patient with microsatellite instability locally advanced rectal cancer: should we adapt our standard management for these patients?
11. 599P R-IMMUNE: A phase Ib/II study to evaluate safety and efficacy of atezolizumab combined with radio-chemotherapy in a preoperative setting for patients with locally advanced rectal cancer (LARC)
12. Neoadjuvant Chemotherapy with Isotoxic High-dose SBRT Does Not Increase Postoperative Complications after Pancreatoduodenectomy for Non-metastatic Pancreatic Cancer
13. Irinotecan in combination with new agents
14. Weekly high-dose 5-fluorouracil and folinic acid in metastatic pancreatic carcinoma: a phase II study of the EORTC GastroIntestinal Tract Cancer Cooperative Group
15. 321P A comprehensive predicting model of recurrence in stage III colon cancer from PETACC-8 trial
16. P-276 Sex and regorafenib toxicity in refractory colorectal cancer: A safety analysis of the RegARd-C trial
17. Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX
18. MON-PO403: Prevalence of Sarcopenia in Old Patients with a Gastrointestinal Cancer Treated with Adjuvant Chemotherapy
19. O-003 - Exploratory analysis based on tumor location of REACHIN, a randomized, double-blinded, placebo-controlled phase 2 trial of regorafenib after failure of gemcitabine and platinum-based chemotherapy for advanced/metastatic biliary tract tumors
20. 1804P - Effect of oral magnesium supplementation on the kinetics of magnesium wasting induced by EGFR targeted antibody therapy for colorectal carcinoma (MAGNET trial)
21. 740P - Final results of a phase II quality of life (QOL) randomized, cross-over (CO) study with gemcitabine (Gem) and nab-paclitaxel (n-P) in locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC): QOLINPAC
22. 462PD - Postoperative carcinoembryonic antigen (CEA) association with survival and oxaliplatin benefit in stage II colon cancer (CC): Post hoc analysis of the MOSAIC trial
23. O-021 - Safety and antitumor activity of pembrolizumab in patients with advanced microsatellite instability–high (MSI-H) colorectal cancer: KEYNOTE-164
24. O-015 - A two arm phase II study of FOLFIRI in combination with standard or escalating dose of cetuximab as first line treatment for metastatic colorectal cancer: Everest 2 final results
25. O-003 - Gemcitabine with nab-paclitaxel in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC): A quality of life randomized cross-over study (QOLINPAC)
26. 480O - Prognostic value of methylator phenotype in stage III colon cancer treated with oxaliplatin-based adjuvant chemotherapy
27. 706P - Prognostic value of the neutrophil-to-lymphocyte ratio in advanced hepatocellular carcinoma: An exploratory analysis from the ARQ197-215 study
28. 461O - Adjuvant FOLFOX+ cetuximab vs FOLFOX in full RAS and BRAF wild type stage III colon cancer patients: Results from the PETACC8 trial
29. 459O - ERBB2 alterations a new prognostic biomarker in stage III colon cancer from a FOLFOX based adjuvant trial (PETACC8)
30. The management of pancreatic cancer. Current expert opinion and recommendations derived from the 8th World Congress on Gastrointestinal Cancer, Barcelona, 2006
31. A Mobile Oncogeriatric Team (MOT) in a Belgian academic hospital: What is the opinion of elderly cancer patients?
32. 749TiP - Regorafenib in Locally Advanced and Metastatic Intrahepatic or Hilar Cholangiocarcinoma: a Randomized Double-Blinded Phase Ii Trial. Reach In
33. 579P - Final Results of a Randomized Phase Ii Study with Neo-Adjuvant Triplet or Doublet Therapy, Radiation and Total Mesorectal Excision for Locally Advanced Rectal Cancer: Axe Beam
34. 572P - Prognostic Value of Kras Mutations in Stage III Colon Cancer: Post-Hoc Analyses of the Petacc8 Phase III Trial
35. 502PD - Mosaic Study: Actualization of Overall Survival (Os) with 10 Years Follow Up and Evaluation of Braf. By Gercor and Mosaic Investigators
36. PP098-SUN PREVALENCE OF STARVATION OR CACHEXIA AT EARLY DIAGNOSIS OF CANCER PATIENTS
37. LBA4 - Adjuvant Folfox4 with or without Cetuximab (CTX) in Patients (PTS) with Resected Stage III Colon Cancer (CC): Dfs and OS Results and Subgroup Analyses of the PETACC8 Intergroup Phase III Trial
38. 669PD - Met as Prognostic Factor and Therapeutic Target in Pretreated Hepatocellular Carcinoma (HCC): Final Results of a Randomized Controlled Phase 2 Trial (RCT) with Tivantinib (ARQ 197)
39. 776TiP - Gamma (Gemcitabine and Amg 479 for Metastatic Adenocarcinoma of the Pancreas): a Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Ganitumab Plus Gemcitabine (G) or Placebo Plus G as First-Line Therapy for Metastatic Pancreatic Cancer
40. 520O - Adjuvant Folfox4 Plus or Minus Cetuximab (CMAB) in Patients (PTS) with Kras Mutant (MKRAS) Resected Stage III Colon Cancer (CC). Results from the PETACC8 Intergroup Trial
41. Phase II study of raltitrexed in combination with oxaliplatin as second line treatment in refractory advanced colorectal cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.